Delucemine

Delucemine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 3,3-Bis(3-fluorophenyl)-N-methylpropan-1-amine;
CAS Number	186495-49-8 ;
PubChem CID	156421;
ChemSpider	137745 ;
UNII	124LSR3H2X;
ChEMBL	ChEMBL2106165 ;
CompTox Dashboard (EPA)	DTXSID20171908 ;
Chemical and physical data
Formula	C16H17F2N
Molar mass	261.316 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F;
	InChI InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3 ; Key:MUGNLPWYHGOJEG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Delucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor, and has neuroprotective effects.^[1]^[2] It was originally investigated for the treatment of stroke and in 2004 was studied as a potential antidepressant.^[3]^[4]^[5]

Origin

The basic structure of delucemine was based on argiotoxin 636, a NMDA antagonist isolated from the venom of the Araneid Argiope aurantia.^[6]^[7]^[8]

References

^ Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D (December 1999). "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies". Annals of the New York Academy of Sciences. 890 (1): 450–7. Bibcode:1999NYASA.890..450M. doi:10.1111/j.1749-6632.1999.tb08023.x. PMID 10668449. S2CID 5629889.
^ Leoni MJ, Chen XH, Mueller AL, Cheney J, McIntosh TK, Smith DH (December 2000). "NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat". Experimental Neurology. 166 (2): 442–9. doi:10.1006/exnr.2000.7513. PMID 11085909. S2CID 39222349.
^ "NPS Pharmaceuticals Inc, Form 10-Q, Quarterly Report, Filing Date May 17, 2004". secdatabase.com. Retrieved May 14, 2018.
^ CA 2599721, Pyke R, Ceci A, "Pharmaceutical compositions for the treatment and/or prevention of depression"
^ WO 2014015047, Ichinose F, Marutani E, Kida K, "Compositions and methods to treat neurodegenerative diseases"
^ Nentwig W (2013-02-15). Spider Ecophysiology. Springer Science & Business Media. ISBN 9783642339899.
^ Oldrati V, Bianchi E, Stöcklin R (February 2013). "Spider Venom Components as Drug Candidates". Spider Ecophysiology. pp. 491–503. doi:10.1007/978-3-642-33989-9_37. ISBN 978-3-642-33988-2.
^ Monge-Fuentes V, Gomes FM, Campos GA, Silva Jd, Biolchi AM, Dos Anjos LC, Gonçalves JC, Lopes KS, Mortari MR (August 2015). "Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders". The Journal of Venomous Animals and Toxins Including Tropical Diseases. 21 (31): 31. doi:10.1186/s40409-015-0031-x. PMC 4529710. PMID 26257776.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D (December 1999). "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies". Annals of the New York Academy of Sciences. 890 (1): 450–7. Bibcode:1999NYASA.890..450M. doi:10.1111/j.1749-6632.1999.tb08023.x. PMID 10668449. S2CID 5629889.

[2] Leoni MJ, Chen XH, Mueller AL, Cheney J, McIntosh TK, Smith DH (December 2000). "NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat". Experimental Neurology. 166 (2): 442–9. doi:10.1006/exnr.2000.7513. PMID 11085909. S2CID 39222349.

[NPS-Pharmaceuticals-Inc-May-2004-10-Q-3] "NPS Pharmaceuticals Inc, Form 10-Q, Quarterly Report, Filing Date May 17, 2004". secdatabase.com. Retrieved May 14, 2018.

[4] CA 2599721, Pyke R, Ceci A, "Pharmaceutical compositions for the treatment and/or prevention of depression"

[5] WO 2014015047, Ichinose F, Marutani E, Kida K, "Compositions and methods to treat neurodegenerative diseases"

[6] Nentwig W (2013-02-15). Spider Ecophysiology. Springer Science & Business Media. ISBN 9783642339899.

[7] Oldrati V, Bianchi E, Stöcklin R (February 2013). "Spider Venom Components as Drug Candidates". Spider Ecophysiology. pp. 491–503. doi:10.1007/978-3-642-33989-9_37. ISBN 978-3-642-33988-2.

[8] Monge-Fuentes V, Gomes FM, Campos GA, Silva Jd, Biolchi AM, Dos Anjos LC, Gonçalves JC, Lopes KS, Mortari MR (August 2015). "Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders". The Journal of Venomous Animals and Toxins Including Tropical Diseases. 21 (31): 31. doi:10.1186/s40409-015-0031-x. PMC 4529710. PMID 26257776.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Clinical data

ATC code	none
Identifiers
IUPAC name 3,3-Bis(3-fluorophenyl)-N-methylpropan-1-amine
CAS Number	186495-49-8^Y
PubChem CID	156421
ChemSpider	137745^N
UNII	124LSR3H2X
ChEMBL	ChEMBL2106165^N
CompTox Dashboard (EPA)	DTXSID20171908
Chemical and physical data
Formula	C₁₆H₁₇F₂N
Molar mass	261.316 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
InChI InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3^N Key:MUGNLPWYHGOJEG-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

Delucemine

Origin

See also

References